Nov 09, 2023 / 01:00PM GMT
Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
Everyone, I'm Ellie Merle. Thank you so much for joining us at day 2 of the UBS Biopharma Conference here in sunny Miami. Very happy to have Moderna with us this morning. Joining us from Moderna is James Mock, Chief Financial Officer.
Questions and Answers:
Eliana Rachel Merle - UBS Investment Bank, Research Division - AnalystAnd with that, maybe just starting high level, walk us through the recent update with the 2023 guidance and how you think about COVID numbers from here?
James M. Mock - Moderna, Inc. - CFO
Okay. Well, first off, thanks for having us, Ellie. It's a pleasure to be here. And maybe let me just step back and talk about what we wanted to frame of it, why we get some 3 years of the financial framework here.
So we've always operated under the same principles. Those principles were that we could always have the ability to flex spending. We've showed that in the past. We're always concerned with financing risk. We've
Trustpilot
